Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

Cara Therapeutics Doses First Patient in Phase 1 Trial of Oral KORSUVA™ (CR845/difelikefalin) in Chronic Liver Disease (CLD) Patients

GlobeNewswire February 28, 2018

The Medical and Legal Cannabis Market Projected to Have Positive Future Estimates

PR Newswire February 20, 2018

Cara Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference

GlobeNewswire February 7, 2018

Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus

GlobeNewswire January 31, 2018

Global Cannabis Sales Projected to Grow

PR Newswire January 29, 2018

Legalization Boost Sales in Cannabis Products

PR Newswire January 12, 2018

Data Shows Strong Demand for Medical Cannabis Products

PR Newswire December 27, 2017

Canada's Cannabis Boom Hits New Heights

PR Newswire December 20, 2017

Research Predicts Further Growth for the Medical Cannabis Market

PR Newswire December 18, 2017

Cara Therapeutics to Present at November Investor Conferences

GlobeNewswire November 8, 2017

Cara Therapeutics Reports Third Quarter 2017 Financial Results

GlobeNewswire November 2, 2017

Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting

GlobeNewswire October 31, 2017

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence™-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients

PR Newswire October 31, 2017

Cara Therapeutics to Announce Third Quarter 2017 Financial Results on November 2, 2017

GlobeNewswire October 26, 2017

Cara Therapeutics Doses First Patient in Phase 1 Study of Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients

GlobeNewswire October 25, 2017

Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus

GlobeNewswire October 16, 2017

Cara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference

GlobeNewswire October 4, 2017

Sales of Legal Cannabis Products are Expected to Grow

PR Newswire October 2, 2017

Legal and Medical Cannabis Market Expected to Show Strong Growth

PR Newswire September 26, 2017

Legal and Medical Cannabis Market Investments on the Rise

PR Newswire September 7, 2017